18f03a3f-c2d2-4c3b-a246-e8a78e6aa479
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.360
- INTERFERON_GAMMA_RESPONSE+0.310
- WNT_BETA_CATENIN_SIGNALING+0.270
- XENOBIOTIC_METABOLISM+0.270
- APICAL_JUNCTION+0.230
- HEDGEHOG_SIGNALING+0.220
- MYOGENESIS+0.220
- KRAS_SIGNALING_DN+0.210
- MYC_TARGETS_V2+0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
Top 10 suppressed
- PROTEIN_SECRETION-0.480
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.350
- ANDROGEN_RESPONSE-0.340
- UV_RESPONSE_DN-0.310
- MTORC1_SIGNALING-0.280
- MYC_TARGETS_V1-0.250
- CHOLESTEROL_HOMEOSTASIS-0.220
- ANGIOGENESIS-0.150
- TGF_BETA_SIGNALING-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 002260fb-3015-4876-b8fd-edffd7fc95e8 | — | — | 0.826 |
| 2 | fee5651d-3ac9-474a-84da-4fd0ce06f341 | — | — | 0.817 |
| 3 | 8f518c0d-42e0-4418-bb48-f69b32446b46 | — | — | 0.787 |
| 4 | SRR23303751 | — | — | 0.784 |
| 5 | SRR8613711 | — | D | 0.776 |
| 6 | ca188ec2-4185-4871-b71b-d024a37e5654 | — | — | 0.764 |
| 7 | MNG1108 | — | — | 0.759 |
| 8 | a6b176e9-f4fc-4188-9771-ab2f3e00a4a8 | — | — | 0.757 |
| 9 | MNG132 | — | — | 0.751 |
| 10 | BS_G5QBBHDV | low-grade glioma | — | 0.749 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.080 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.070 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.060 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |